JPS6256133B2 - - Google Patents
Info
- Publication number
- JPS6256133B2 JPS6256133B2 JP11942483A JP11942483A JPS6256133B2 JP S6256133 B2 JPS6256133 B2 JP S6256133B2 JP 11942483 A JP11942483 A JP 11942483A JP 11942483 A JP11942483 A JP 11942483A JP S6256133 B2 JPS6256133 B2 JP S6256133B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- weight
- administration
- blood pressure
- dihydroxycholecalciferol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002220 antihypertensive agent Substances 0.000 claims description 7
- 229940030600 antihypertensive agent Drugs 0.000 claims description 6
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims 1
- 239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000004531 blood pressure lowering effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- -1 triglyceride ester Chemical class 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000001162 anti-hypercalcemic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
本発明は、24・25−ジヒドロキシコレカルシフ
エロールを活性成分として含有する血圧降下剤に
関する。
本発明者等は、健康な人間体内に存在する内因
性のもので安全性の証明されている物質について
鋭意研究した結果、24・25−ジヒドロキシコレカ
ルシフエロール(以下、本物質又は24・25−
(OH)2−D3と略す)が幾多の生理活性作用を有す
ることを知見し、既に抗高カルシウム血症作用、
抗潰瘍作用、免疫機能低下防止作用、マグネシウ
ム代謝調節作用、抗高リン血症作用、血糖調節作
用、抗腫瘍作用を見出している。その後、研究を
重ねた結果、後記するごとき血圧降下作用を有す
ることを知見し、本発明に到達した。
本物質は後述するごとく安全性の高い物質であ
り、且つ血圧降下作用を有しており、抗高血圧剤
として有用である。
本物質はいずれも公知物質で次のような構造を
有し、例えばAnthony W.Norman、Vitamin
D:MOLECULAR BICLOGY AND CLINICAL
NUTRITION、MARCEL DEKKER、INC.p.1〜
92(1980)に開示されている。
本物質は24R・25−(OH)2−D3、24S・25−
(OH)2−D3又はこれらの混合物であつてもよいが
特に24R・25−(OH)2−D3であることが好まし
い。本発明の血圧降下剤は活性成分として上記の
物質を含有し、下記に示すごとき種々の製剤形態
で用いられる。本発明の血圧降下剤は、経口的、
非経口的経路又は直腸経路で投与され得るが、経
口投与が好ましい。
本物質を有効成分とする製剤は、錠剤、散剤、
顆粒剤、坐剤、カプセル剤、アルコール溶液剤、
油性溶液剤、水性懸濁液剤などの投与形態で用い
られる。又油性溶媒としては、中級脂肪酸のトリ
グリセライドエステル、コーン油、綿実油、落花
生油、魚肝油、油状エステルなどが用いられる。
又カカオ油、グリセリン等も好ましい。その他の
成分として乳糖、でんぷん、タルク、ステアリン
酸マグネシウム、ソルビン酸、ソルビン酸の塩、
糖又はその誘導体アルコール、生理食塩水、界面
活性剤、酸化防止剤またはその他の医薬剤等を本
物質と併用し得る。
本物質は、単位投与形態の中に2×10-5〜4重
量%、好ましくは2×10-4〜1重量%含有し得
る。又、本物質は成人に対し1日当り0.1μg〜
1×105μg、好ましくは0.5〜1×104μg投与
する。
次に本物質の急性毒性を調べた結果を記す。
急性毒性:
ICR系雄マウス(体重25±3g)10匹を用いて
本物質をエタノールに溶解し、エタノール濃度が
2%になるように中級脂肪酸のトリグリセライド
エステルに溶解し、経口(p.o.)投与した。投与
量は100mg/Kgである。投与後2週間中毒症状に
ついて観察したが10匹とも異常なく生存した。屠
殺後、血液、生化学検査、解剖所見、病理組織学
的検索を行なつたが、2%エタノール含有中級脂
肪酸のトリグリセライドエステルのみを投与した
コントロール群と何らかわるところがなかつた。
従つて、本物質の経口投与のLD50の値は100mg/
Kg以上であるので、活性型ビタミンD3アナログ
といわれている1α−(OH)−D3(経口投与の
LD50は1mg/Kg以下である)と比較して本物質
は極めて安全なものといえる。
以下に実施例を例示して本発明の効果を具体的
に説明する。なお、実施例中で使用した本物質は
24R・25−(OH)2−D3であり、その24位の光学異
性体の構造確認はTetrahedron Letters No.26、
p.2203〜2206、1975を参照して行なつた。
実施例 1
血圧降下作用
自然発症高血圧ラツト(SHR)に対して、C8
〜C10のカルボン酸のトリグリセライドエステル
(以下、MCTと略す)に溶解した本物質を100μ
g/Kgとなるよう経口投与した。投与後6時間及
び12時間目に血圧測定器(ウエダ製作所製、
USM−105R型)を用いて血圧を測定し、投与前
後の血圧の差をもつて本物質の降圧効果とした。
尚、MCTのみの投与を対照とした。
前記自然発症高血圧ラツトの本物質及び対照物
質投与前の血圧は194mmHgであつた。
結果は下記表−1に示す。本物質はいずれも明
らかに降圧効果を示し、血圧降下剤として有用で
ある。
The present invention relates to an antihypertensive agent containing 24,25-dihydroxycholecalciferol as an active ingredient. As a result of intensive research into a substance that is endogenous to the healthy human body and has been proven to be safe, the present inventors discovered 24,25-dihydroxycholecalciferol (hereinafter referred to as this substance or 24,25-dihydroxycholecalciferol). −
(OH) 2 -D 3 ) has been found to have numerous physiologically active effects, and has already been shown to have anti-hypercalcemic and anti-hypercalcemic effects.
It has been found to have anti-ulcer effects, prevent immune function decline, regulate magnesium metabolism, anti-hyperphosphatemia, regulate blood sugar, and anti-tumor effects. Subsequently, as a result of repeated research, it was discovered that it has a blood pressure lowering effect as described later, and the present invention was achieved. As described below, this substance is a highly safe substance, has a blood pressure lowering effect, and is useful as an antihypertensive agent. All of these substances are known substances and have the following structures. For example, Anthony W.Norman, Vitamin
D: MOLECULAR BICLOGY AND CLINICAL
NUTRITION, MARCEL DEKKER, INC.p.1~
92 (1980). This substance is 24R・25−(OH) 2 −D 3 , 24S・25−
(OH) 2 -D 3 or a mixture thereof may be used, but 24R.25-(OH) 2 -D 3 is particularly preferred. The antihypertensive agent of the present invention contains the above-mentioned substances as active ingredients, and can be used in various formulations as shown below. The antihypertensive agent of the present invention can be administered orally;
Although administration may be by parenteral or rectal routes, oral administration is preferred. Preparations containing this substance as an active ingredient include tablets, powders,
Granules, suppositories, capsules, alcohol solutions,
It is used in dosage forms such as oily solutions and aqueous suspensions. As the oily solvent, triglyceride esters of intermediate fatty acids, corn oil, cottonseed oil, peanut oil, fish liver oil, oily esters, etc. are used.
Also preferred are cacao oil and glycerin. Other ingredients include lactose, starch, talc, magnesium stearate, sorbic acid, sorbic acid salts,
Sugar or its derivative alcohol, physiological saline, surfactants, antioxidants, or other pharmaceutical agents may be used in combination with this substance. The substance may be contained in a unit dosage form from 2x10 -5 to 4% by weight, preferably from 2x10 -4 to 1% by weight. In addition, this substance is 0.1 μg per day for adults.
1×10 5 μg, preferably 0.5 to 1×10 4 μg is administered. Next, we will describe the results of investigating the acute toxicity of this substance. Acute toxicity: This substance was dissolved in ethanol and triglyceride ester of intermediate fatty acids to give an ethanol concentration of 2%, and administered orally (po) to 10 male ICR mice (body weight 25±3 g). . The dose is 100mg/Kg. The animals were observed for symptoms of toxicity for two weeks after administration, but all 10 animals survived without any abnormalities. After slaughter, blood, biochemical tests, autopsy findings, and histopathological examinations were performed, but there was no difference in any way from the control group to which only triglyceride ester of intermediate fatty acid containing 2% ethanol was administered.
Therefore, the LD 50 value for oral administration of this substance is 100mg/
1α-(OH)-D 3 (orally administered), which is said to be an active vitamin D 3 analogue.
(LD 50 is less than 1 mg/Kg), this substance can be said to be extremely safe. EXAMPLES The effects of the present invention will be specifically explained below with reference to Examples. In addition, this substance used in the examples is
24R・25−(OH) 2 −D 3 , and the structure of the optical isomer at position 24 was confirmed in Tetrahedron Letters No.26,
This was done with reference to p.2203-2206, 1975. Example 1 Blood pressure lowering effect C8 on spontaneously hypertensive rats (SHR)
~100μ of this substance dissolved in C10 carboxylic acid triglyceride ester (hereinafter abbreviated as MCT)
It was administered orally at a concentration of g/Kg. 6 and 12 hours after administration, a blood pressure measuring device (manufactured by Ueda Seisakusho,
Blood pressure was measured using a USM-105R model), and the difference in blood pressure before and after administration was determined as the antihypertensive effect of this substance.
Note that administration of MCT alone was used as a control. The blood pressure of the spontaneously hypertensive rats before administration of the present substance and the control substance was 194 mmHg. The results are shown in Table 1 below. All of these substances clearly exhibit antihypertensive effects and are useful as antihypertensive agents.
【表】
実施例 2
アルゴンをバフリングしながら400W高圧水銀
ランプで72時間照射してパーオキシドを消失・除
去せしめたMCT1Kgに24R・25−(OH)2−D3を0.5
μg含有するように下記剤皮成分を加温溶解し軟
カプセル製造機を用いて常法により軟カプセル剤
を作製した。
剤皮処方例
ゼラチン 10重量部
グリセリン 2重量部
防腐剤(エチルパラベン) 0.05重量部
チタンホワイト 0.2重量部
水 0.2重量部
(最終形態に於ける重量部)
同様にして1カプセル中に1μg、2μg、5
μg又は10μg含有するものをそれぞれ作製し
た。[Table] Example 2 1kg of MCT was irradiated with a 400W high-pressure mercury lamp for 72 hours while buffing with argon to eliminate and eliminate peroxide, and 0.5 of 24R・25−(OH) 2 −D 3 was added to it.
The following shell components were heated and dissolved so as to contain μg, and soft capsules were prepared by a conventional method using a soft capsule making machine. Shell formulation example Gelatin 10 parts by weight Glycerin 2 parts by weight Preservative (ethylparaben) 0.05 parts by weight Titanium white 0.2 parts by weight Water 0.2 parts by weight (parts by weight in final form) Similarly, 1 μg, 2 μg, 5
Products containing μg or 10 μg were prepared, respectively.
Claims (1)
を有効成分とする血圧降下剤。 2 24・25−ジヒドロキシコレカルシフエロール
が24R・25−ジヒドロキシコレカルシフエロール
であることを特徴とする特許請求の範囲第1項に
記載の血圧降下剤。[Claims] 1. A hypotensive agent containing 24,25-dihydroxycholecalciferol as an active ingredient. 2. The antihypertensive agent according to claim 1, wherein the 24,25-dihydroxycholecalciferol is 24R,25-dihydroxycholecalciferol.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11942483A JPS6011419A (en) | 1983-06-30 | 1983-06-30 | Blood pressure controlling agent |
US06/620,923 US4501738A (en) | 1983-06-30 | 1984-06-15 | Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat pain, pyrexia or inflammatory diseases |
IT21627/84A IT1176336B (en) | 1983-06-30 | 1984-06-27 | Use of 24,25:di:hydroxy cholecalciferol |
BE0/213228A BE900026A (en) | 1983-06-30 | 1984-06-28 | PHARMACEUTICAL COMPOSITION CONTAINING 24,25-DIHYDROXY-CHOLECALCIFEROL. |
US06/656,760 US4534975A (en) | 1983-06-30 | 1984-10-01 | Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11942483A JPS6011419A (en) | 1983-06-30 | 1983-06-30 | Blood pressure controlling agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6011419A JPS6011419A (en) | 1985-01-21 |
JPS6256133B2 true JPS6256133B2 (en) | 1987-11-24 |
Family
ID=14761106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11942483A Granted JPS6011419A (en) | 1983-06-30 | 1983-06-30 | Blood pressure controlling agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6011419A (en) |
-
1983
- 1983-06-30 JP JP11942483A patent/JPS6011419A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6011419A (en) | 1985-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2722227B2 (en) | Fatty acid composition | |
WO2014179325A1 (en) | Omega-3 fatty acid formulations for use as pharmaceutical treatment | |
EP0336851A1 (en) | Pharmaceutical composition for oral administration containing a diphosphonic acid derivative | |
JP2775627B2 (en) | Therapeutic composition | |
JPH0132208B2 (en) | ||
CA2905671A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
TWI284529B (en) | A composition for lowering triglyceride | |
JPH05186340A (en) | Orally administering drug in aqueous solution form containing ubiquinone | |
JP3092180B2 (en) | Low density lipoprotein receptor activator | |
KR20240036651A (en) | How to Inhibit the Progression of Oxidative Retinal Disease | |
JPS6256133B2 (en) | ||
JPS6221333B2 (en) | ||
WO2004062626A2 (en) | Composition and method for treating age-related disorders | |
JP2876547B2 (en) | Anti-Kur disease agent | |
JPH0210127B2 (en) | ||
JPS6221328B2 (en) | ||
JP2629844B2 (en) | Antiparasitic agent | |
JPS6221330B2 (en) | ||
JPH0319208B2 (en) | ||
JP4896531B2 (en) | Pharmaceutical composition for increasing blood CoQ10 level | |
JPH0372206B2 (en) | ||
JPH08208464A (en) | Agent for treatment and prevention of hyperlipemia | |
CN118019529A (en) | Methods of inhibiting progression of oxidative retinal disease | |
JPS6221332B2 (en) | ||
JPH0371411B2 (en) |